Alsetの空売り状況は、投資家がAlsetの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Alset (NASDAQ:AEI) 株価情報, 空売り情報

Alset

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

Alset Inc

Advanced Energy Industries, Inc. - Common Stock

Advanced Energy Industries Inc

Aei Income & Growth Fund LP

UBS analyst Taylor McGinnis maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and lowers the price target from $55 to $35.

News

Price Target

Analyst Ratings

FIVN

UBS Maintains Buy on Five9, Lowers Price Target to $35

UBS analyst Damian Karas maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $56 to $53.

CGNX

UBS Maintains Buy on Cognex, Lowers Price Target to $53

UBS analyst Peter Grom maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Neutral and lowers the price target from $110 to $102.

UBS Maintains Neutral on Church & Dwight Co, Lowers Price Target to $102

UBS analyst John Lovallo maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and lowers the price target from $180 to $163.

BLDR

UBS Maintains Buy on Builders FirstSource, Lowers Price Target to $163

UBS analyst Joshua Spector maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and lowers the price target from $335 to $324.

UBS Maintains Buy on Air Products & Chemicals, Lowers Price Target to $324

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and lowers the price target from $355 to $310.

UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310

UBS analyst Trung Huynh maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and lowers the price target from $319 to $315.

AMGN

UBS Maintains Neutral on Amgen, Lowers Price Target to $315

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 8.33% on an annualized basis producing an average annual return of 22.97%. Currently, Devon Energy has a market capitalization of $20.23 billion. 
Buying $100 In DVN: If an investor had bought $100 of DVN stock 5 years ago, it would be worth $275.31 today based on a price of $31.44 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Devon Energy 5 Years Ago Would Be Worth This Much Today

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

ALNY

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

UBS analyst Kevin Caliendo maintains Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) with a Neutral and raises the price target from $16 to $17.

ALHC

UBS Maintains Neutral on Alignment Healthcare, Raises Price Target to $17

UBS analyst Joseph Spak maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Neutral and raises the price target from $58 to $66.

APTV

UBS Maintains Neutral on Aptiv, Raises Price Target to $66

UBS analyst Gavin Parsons maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Neutral and raises the price target from $120 to $155.

UBS Maintains Neutral on Howmet Aerospace, Raises Price Target to $155

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Buy and raises the price target from $21 to $22.

FOLD

UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22

UBS analyst Peter Grom maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and raises the price target from $60 to $62.

UBS Maintains Neutral on Estee Lauder Cos, Raises Price Target to $62

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $160 to $170.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $170

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $67 to $71.

UBS Maintains Neutral on CVS Health, Raises Price Target to $71

UBS analyst Eliana Merle maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $78 to $70.

MRNA

UBS Maintains Buy on Moderna, Lowers Price Target to $70

Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.45%. Currently, Casey's General Stores has a market capitalization of $16.70 billion. 
Buying $100 In CASY: If an investor had bought $100 of CASY stock 5 years ago, it would be worth $299.50 today based on a price of $458.65 for CASY at the time of writing.
<h3>Casey's General Stores's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASY

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $441 to $458.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $458

UBS analyst Joshua Spector maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Neutral and raises the price target from $21 to $22.

Comments

Alset

空売り

Alset (NASDAQ:AEI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル